Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast Cancer

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast CancerПодробнее

Dr. Joyce O’Shaughnessy on Promising Agents in Triple-Negative Breast CancerПодробнее

Joyce O’Shaughnessy, MD: Treatment Goals for Patients With TNBC and Multiple Metastatic SitesПодробнее

Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic AgentsПодробнее

Dr. O’Shaughnessy on the Utility of Tucatinib in the HER2+ Breast Cancer Brain MetastasesПодробнее

Dr. Joyce O'Shaughnessy on Eribulin in Metastatic Breast CancerПодробнее

Data + Perspectives: HR-Positive Breast Cancer (1 of 5)Подробнее

Understanding the ExteNET TrialПодробнее

Dr. O'Shaughnessy on the Future of Breast Cancer BiomarkersПодробнее

Dr. Joyce O'Shaughnessy on Treatment With Everolimus in Advanced Breast CancerПодробнее

Dr. Joyce O'Shaughnessy invites you the International Congress on the Future of Breast CancerПодробнее

Dr. O’Shaughnessy on Clinical Implications of the TEXT and SOFT Trials in Breast CancerПодробнее

PrecisCa Breast Cancer Awareness Month: Joyce O'Shaughnessy, MDПодробнее

Copy of Dr. O’Shaughnessy on Clinical Implications of the TEXT and SOFT Trials in Breast CancerПодробнее

Dr. O’Shaughnessy on Eribulin as First-Line Therapy for Metastatic HER2-Negative Breast CancerПодробнее

Dr. O'Shaughnessy on the Future of Breast Cancer TreatmentПодробнее

Join Dr. O'Shaughnessy, MD this July for the latest in Breast Cancer CareПодробнее

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBCПодробнее

plasmaMATCH Findings Play an Important Role in the Breast Cancer SettingПодробнее

Disease Heterogeneity in Patients w/Metastatic Breast Cancer | Insights from Dr Joyce O’ShaughnessyПодробнее